

Message from the Chairman

Shane Nichols

As our Section approaches its 50th anniversary, it is my pleasure to report that we are looking forward to what will be the most active year in the Section's history. Although our profession has not been spared the impact of continuing economic uncertainty, the IP Law Section continues to grow and prosper. With more than 1100 members, our Section remains one of the largest of the State Bar of Georgia's sections. Thanks to the hard work of our outgoing Chairman, Steve Wigmore, and the committees that served last year, we are heading into this 2011-2012 term with a great deal of positive momentum.

This year, the Section has formed several new committees to address the evolving needs of our members (a full listing of the 2011-2012 committees is provided on the back page of this newsletter). For the first time ever, for example, we will have a committee specifically dedicated to the interests of patent agents – a critical and growing sector of our profession. Although patent agents cannot become members of the Section unless they are also members of the State Bar, we have made a special arrangement with the Bar under which patent agents will be treated as virtual members so that they can keep apprised of and participate in most of the Section's activities and events. **Susanne Hollinger**, in-house IP counsel at Emory University, will serve as the first chairwoman of the new Patent Agents Committee.



We are also excited about our new committee dedicated to fostering the Section's good relations with law professors and judges. Emory Law Professor, **Timothy Holbrook**, has agreed to head up the new Academic and Judicial Relations Committee. Among other functions, this committee will seek to maintain and enhance the successful relationship the Section has built with the Federal Circuit Court of Appeals in recent years.

On the heels of the Federal Circuit's standing-room-only visit to Atlanta last November, the Section will host a "full panel" of Federal Circuit judges at this year's **IP Law Institute**. **Judges Clevenger, Prost, and Moore** have accepted our invitations to join us at the IP Law Institute in November. After taking a year off to host the Federal Circuit's sitting in Atlanta, the Section will renew its long-standing tradition and present the 2011 IP Law Institute as part of the 23rd Annual North American Entertainment, Sports, and Intellectual Property Law Conference. The Institute will be held **November 9-13, 2011** in **Cabo San Lucas, Mexico**, and will feature many prominent speakers addressing the most compelling topics and trends affecting our profession. Please try to take advantage of this great tradition this year.

Finally, it is my sad duty to report on the untimely passing of one of the Section's most active and popular members, Philip Walden. We are grateful to be able to publish in this issue a tribute to Philip, written by his friend, John Herman, who has known Philip since they were summer associates at King & Spalding in 1991. We will miss Philip.

We have a lot to look forward to this year, as we do our best to follow in the IP Law Section's nearly 50-year tradition of success. It is a privilege to be your Chairman, and I hope you will seek out opportunities to actively participate in the many excellent educational and social events the Section will host in the coming year.

Editor

Chris Curfman

Inside This Issue

FEATURE: *Therasense*:
Dismantling the Atomic
Bomb of Patent Defenses
pg. 3

IP Golf Tournament
pg. 4

In Memoriam
pg. 8

2010-2011 Wrap-Up

Steve Wigmore

The end of this June brought an end to the 2010-2011 bar year. I am very grateful to have served our IP Law Section as its Chair for this term. We had another successful bar year because of the numerous devoted lawyers that are on our executive committee and our regular committees. Our executive committee includes its officers and the chairs of each regular committee.

Our 2010-2011 officers were: Chair Elect, Shane Nichols; Vice Chair, Philip Burrus; Secretary, Tina McKeon and Treasurer, Brad Groff

Our 2010-2011 committee chairs were:

- Licensing: Andria E. Beeler-Norrholm & Susanne Hollinger
- Website: Lauren Fernandez Staley
- Litigation: Wilson White
- Copyright: Joe Staley & Arvind Reddy
- Social: Lauren Estrin
- Newsletter: Chris Curfman & George D. Medlock, Jr.
- In-House: Kevin Glidewell
- Trademark: Robert Dulaney & Steve Risley
- Patent: Rivka Monheit
- CAFC to Atlanta: Chad Pannell



Special recognition is also given to the Georgia State Bar Section Liaison, Derrick Stanley. Derrick helps our IP Law Section organize each program that is convened in State Bar Center and some programs off-site. He is also responsible for distributing the information for all of our Law Section's events.

The executive committee and the regular committees organized ten lunchtime CLE programs this bar year in addition to the Federal Practitioner's Institute (FPI) that featured several Judges from the U.S. Court of the Appeals of the Federal Circuit. The Federal Practitioner's Institute (FPI) was organized as part of the Court's visit to Atlanta. The Court selects one U.S. city each year in which to visit during the first week in November. We offer extra thanks to Chad Pannell of King & Spalding and Professor Tim Holbrook of Emory University for helping to coordinate the Court's visit to Atlanta. We also recognize and thank Jim Brookshire of the Federal Bar Association and Mary Lynne Johnson of the Atlanta Bar Association for help making the FPI and the Court's visit such a success.

I hope you were able to take advantage of these well-organized CLE programs in addition to our annual holiday party held in December 2010 at the Four Seasons Hotel in midtown. Our holiday party is always a great event to catch up with colleagues and friends. Another social event for this bar year was our annual Summer Associate Welcoming Event held in June. This was another opportunity for members to meet some old faces as well as new ones.

In addition to our CLE programs and social events, we also conducted a survey in January 2011 to help our Executive Committee navigate through the years ahead. We appreciate all of those members who responded to our survey.

This note should convey to our members and readers of our IP Section Newsletter that our Executive Committee and our regular committees work hard to bring value to your IP Law Section membership. What is amazing about our IP Law Section is that all of this work is done gratis -- a true volunteer effort by its IP Law Section members for its members.

FEATURE

Therasense: Dismantling the Atomic Bomb of Patent Defenses

Daniel J. Santos

On May 25, 2011, the Court of Appeals for the Federal Circuit (CAFC) issued a long-awaited en banc decision in *Therasense, Inc. v. Becton, Dickinson & Co.*, 2011 U.S. App. LEXIS 10590 (Fed. Cir. 2011). The decision raises the standard for proving inequitable conduct and presumably will make it much more difficult for defendants to succeed on the inequitable conduct defense, which has often been referred to as the “atomic bomb” of patent defenses due to its immensely destructive effects on patent rights.

In a 6-1-4 decision, the court held: (1) the sliding scale test for materiality and intent no longer applies, (2) materiality and intent must be separately proven by clear and convincing evidence, (3) specific intent to deceive the United States Patent & Trademark Office (hereinafter PTO) cannot be inferred unless such inference is the only reasonable inference that can be drawn from the evidence, (4) materiality requires a finding that, but for the information not being disclosed to the PTO, the claim at issue would not have been allowed, and (5) even if materiality and intent are proven by clear and convincing evidence, the patent will only be held to be unenforceable if the patentee’s misconduct resulted in the unfair benefit of receiving an unwarranted claim. The court carved out an exception to the but-for materiality requirement for cases where egregious affirmative misconduct on the part of the patentee is proven.

Background

At the core of the decision were claims in U.S. Patent No. 5,820,551 (hereinafter the ‘551 patent) issued to Therasense, Inc. (now Abbott Diabetes Care, Inc.). The claims at issue were directed to disposable blood glucose test strips for diabetes management. Among other elements of the claims, the claims recite an active electrode “configured to be exposed to said whole blood sample without an intervening membrane or other whole blood filtering member....” The claims had been repeatedly rejected by the examiner over another patent owned by Abbott, U.S. Patent No. 4,545,382 (hereinafter the ‘382 patent). In discussing protective membranes, the disclosure of the ‘382 patent reads, “[o]ptionally, but preferably when being used on live blood, a protective membrane surrounds both the enzyme and the mediator layers, permeable to water and glucose molecules.” The examiner found that this language taught exposing an active electrode to a whole blood sample without an intervening membrane or other whole blood filtering member, as recited in the claims of the ‘551 patent.

In order to overcome the examiner’s rejection, the prosecuting attorney submitted a declaration by Abbott’s Director of Research and Development stating that “one skilled in the art would have felt that an active electrode comprising an enzyme and a mediator would require a protective membrane if it were to be used with a whole blood sample.” Concurrently with the submission of the declaration, the prosecuting attorney submitted arguments that one skilled in the art would not have read this portion of the ‘382 patent as teaching that a protective membrane is optional when used with whole blood samples.


Many years earlier, during the prosecution of a counterpart application to the ‘382 patent in the European Patent Office (EPO), the European patent counsel for Abbott had argued in briefs submitted to the EPO that it was “unequivocally clear” from the disclosure that the protective membrane was optional, but preferred, when being used on live blood.

Subsequently, during the litigation in the district court, the court held that the ‘551 patent was unenforceable on grounds that the failure of Abbott to disclose the EPO briefs to the EPO constituted inequitable conduct. *Therasense, Inc. v. Becton, Dickinson & Co.*, 560 F. Supp. 2d 835 (N.D. Cal. 2008). On the first appeal, the CAFC affirmed the district court’s findings of invalidity, noninfringement and unenforceability. *Therasense, Inc. v. Becton, Dickinson & Co.*, 593 F.3d 1289 (Fed. Cir. 2010). Abbott petitioned the court for an en banc rehearing. Recognizing that there were problems associated with the overuse and expansion of the inequitable conduct doctrine, the court granted the petition and vacated its prior affirmation of the district court’s findings of invalidity, noninfringement and unenforceability. *Therasense, Inc. v. Becton, Dickinson & Co.*, 374 Fed. Appx. 35 (Fed. Cir. 2010).

Majority Opinion

1. Origin of the Inequitable Conduct Doctrine

The majority opinion was written by Chief Judge Rader and joined in full by Judges Newman, Lourie, Linn, Moore and Reyna. In the en banc *Therasense* decision, the court discussed the evolution of the judicially-created doctrine of inequitable conduct from a trio of U.S. Supreme Court cases that applied the doctrine of unclean hands to dismiss patent cases involving egregious misconduct: *Keystone Driller Co. v. General Excavator Co.*, 290 U.S. 240 (1933), *Hazel-Atlas Glass Co.*



Continued, next page

Therasense: Dismantling the Atomic Bomb of Patent Defenses

Continued

v. Hartford-Empire Co., 322 U.S. 238 (1944), *overruled on other grounds by Standard Oil Co. v. United States*, 429 U.S. 17 (1976), and *Precision Instruments Manufacturing Co. v. Automotive Maintenance Machinery Co.*, 324 U.S. 806 (1945). All of these cases involved affirmative acts of deception on the part of the patentee before the PTO and/or the courts. *Keystone* involved suppression of evidence. *Hazel-Atlas* involved both the manufacture and suppression of evidence. *Precision* involved perjury before the PTO and suppression of the perjury before the court.

In discussing this trio of cases and the evolution of the inequitable conduct doctrine, the CAFC explained how the inequitable conduct doctrine had diverged from the unclean hands doctrine and had come to encompass, in addition to affirmative acts of misconduct, mere nondisclosure of information before the USPTO. The court discussed how the potency of the remedy for inequitable conduct had increased to include unenforceability of the entire patent rather than mere dismissal of the instant suit. The court discussed how the increased potency of the remedy for inequitable conduct had led the court in prior decisions to require findings of both intent to deceive and materiality in order to find inequitable conduct.

The court acknowledged that the standards of materiality and intent applied by the court had fluctuated over time from standards for intent that could be met by showing negligence or gross negligence (should have known that the withheld reference was material) to the sliding scale test where inequitable conduct could be proved by a high showing of materiality combined with a low showing of intent, and vice versa.

The court also discussed at length the detrimental effects that overuse of the inequitable conduct defense has had on the PTO, the courts, patentees, and attorneys, including, for example, discouraging settlement, deflecting attention from the merits of invalidity and infringement issues, increasing the complexity, duration and cost of litigation, attacking the reputation of the prosecuting attorney, and increasing the number of references of only marginal value that are disclosed to the PTO. The court referred to its previous decision in *Aventis Pharma S.A. v. Amphastar Pharm., Inc.*, 525 F.3d 1334, 1349 (Fed. Cir. 2008) (Rader, J., dissenting) characterizing the inequitable conduct defense as the “atomic bomb” of patent law in that, unlike invalidity defenses that are directed to individual claims, inequitable conduct regarding any single claim can

Continued, next page

REMINDER: 2nd Annual Charity IP Golf Tournament

On behalf of Georgia State University Intellectual Property, the IP Law Section of the State Bar of Georgia, and the IP Section of the Atlanta Bar Association, you are cordially invited to the 2nd Annual Charity Intellectual Property Golf Tournament (a/k/a the CIP CUP) on **Monday, October 24, 2011, at 10 a.m.** at the Alpharetta Athletic Club in Alpharetta, GA.

Proceeds from this event will go to the Georgia Lawyers for the Arts, the Public Interest Law Association and the Intellectual Property Scholarship Fund at Georgia State University.

The sponsorship cost for a foursome is \$1,500. This includes all golf/club fees for the foursome. Lunch and beverages will be provided. Sponsors will receive promotional consideration, including recognition at the event, recognition on the GSU Intellectual Property website and email fliers, and recognition at the IP Legends Award ceremony. Other sponsorship options and opportunities are available upon request.

Space is limited. There is a maximum of two foursomes per sponsoring law firm or sponsoring corporation. Don't miss an opportunity to mingle with in-house and law firm practitioners, or to entertain a favorite client or two. **The initial registration period ends on September 15, 2011.** If you would like to sponsor a foursome for the event, are interested in other sponsorship opportunities, or would like additional details about the event and how to register, please contact Cheryl Tubach at cheryl.tubach@huber.com or Todd Obijeski at tobjeski@merchantgould.com.

The team format for the golf tournament is a 2-person best ball. Prizes for the foursomes with the lowest net score and the lowest gross score will be awarded, as well as individual prizes for the closest to the pin and longest drive. The foursome with the lowest net score also will be awarded the Charity Intellectual Property “CIP” Cup.

Who will bring home the CIP Cup in 2011?



Therasense: Dismantling the Atomic Bomb of Patent Defenses

Continued

render the entire patent unenforceable, cannot be cured by reissue, can spread from a single patent to render unenforceable related applications and patents, can lead to awards of attorneys fees, and can give rise to antitrust and unfair competition claims.

2. Raising the Intent Standard

After discussing the origins of the inequitable conduct doctrine and public policy arguments that justify raising the standard for inequitable conduct, the court set forth a higher standard for inequitable conduct that purportedly will realign it with the unclean hands doctrine and reduce its overuse. In doing so, the court relied heavily on its holdings in *Star Scientific Inc. v. R.J. Reynolds Tobacco Co.*, 537 F.3d 1357 (Fed. Cir. 2008) and *Kingsdown Med. Consultants, Ltd. v. Hollister Inc.*, 863 F.2d 867, 877 (Fed. Cir. 1988). In particular, the court held that in order to prove intent, the defendant must prove by clear and convincing evidence that the applicant knew of a reference, knew that it was material, and made a deliberate decision to withhold it. The court explained that the requirement of knowledge and deliberate action had its origin in the trio of U.S. Supreme Court unclean hands cases, *Keystone*, *Hazel-Atlas* and *Precision*. The court also held that the sliding scale test, which has been applied in cases such as *Digital Equipment Corp. v. Diamond*, 653 F.2d 701 (1st Cir.1981), *Am. Hoist & Derrick Co. v. Sowa & Sons, Inc.*, 725 F.2d 1350 (Fed. Cir. 1984), *Union Pac. Res. Co. v. Chesapeake Energy Corp.*, 236 F.3d 684 (Fed. Cir. 2001), and *Digital Control Inc. v. Charles Mach. Works*, 437 F.3d 1309 (Fed. Cir. 2006), should not be used by district courts.

In addition, the court held that while specific intent to deceive may be inferred from the evidence, specific intent to deceive must be “the single most reasonable inference able to be drawn from the evidence,” quoting *Star Scientific*, 537 F.3d at 1366. The court held that the evidence “must be sufficient to require a finding of deceitful intent in the light of all the circumstances,” quoting *Kingsdown*, 863 F.2d at 873. The court further held that because the party alleging inequitable conduct bears the burden of proof, the “patentee need not offer any good faith explanation unless the accused infringer first . . . prove[s] a threshold level of intent to deceive by clear and convincing evidence,” quoting *Star Scientific*, 537 F.3d at 1368.

3. Raising the Materiality Standard

After setting forth the higher standard for proving intent, the court noted that the higher intent standard alone would not be sufficient to curb overuse of the inequitable conduct defense and would not cure the problem of over-disclosure of marginally relevant prior art to the PTO. For these reasons, the court also raised the materiality standard. The court found support for raising the standard in *Corona Cord Tire Co. v. Dovan Chemical Corp.*, 276 U.S. 358 (1928). That case involved submission by the patentee of two affidavits to the PTO that falsely claimed that the invention had been used in the production of rubber goods when in fact only test slabs of rubber had been produced. The Court held that because the misrepresentations were not the but-for cause of the patent’s issuance, they were

immaterial and refused to extinguish the patent’s presumption of validity.

After laying the ground work for raising the materiality standard based on the holding set forth in *Corona Cord*, the CAFC went on to hold:

as a general matter, the materiality required to establish inequitable conduct is but-for materiality. When an applicant fails to disclose prior art to the PTO, that prior art is but-for material if the PTO would not have allowed a claim had it been aware of the undisclosed prior art. Hence, in assessing the materiality of a withheld reference, the court must determine whether the PTO would have allowed the claim if it had been aware of the undisclosed reference. In making this patentability determination, the court should apply the preponderance of the evidence standard and give claims their broadest reasonable construction.

Thus, under the but-for materiality standard adopted by the court, a reference is not material unless the reference taken alone or in combination with other references would have rendered the claim unpatentable by a preponderance of the evidence.

The court explained that it is possible for a reference to be material under the higher but-for standard even if a court would not have rendered the claim at issue invalid because courts must find invalidity by the higher standard of clear and convincing evidence rather than by the lower, preponderance of the evidence standard. Conversely, the court also noted that if a claim is found by a court to be invalid over the reference taken alone or in combination with other references by clear and convincing evidence, the reference necessarily meets the but-for materiality standard adopted by the court. In the latter case, therefore, knowledge of the reference coupled with deliberate failure to disclose the reference to the PTO could lead to a finding of inequitable conduct.

In adopting the higher standard for materiality, the court refused to adopt the definition for materiality set forth in 37 CFR §1.56 (hereinafter PTO Rule 56). As discussed below, this was a major point of contention between the majority and the dissent, which argued that the definition of materiality applied by the courts should be the definition supplied in PTO Rule 56.

4. Raising the Overall Standard for Inequitable Conduct

In addition to raising the standards for materiality and intent, the CAFC further raised the overall standard for inequitable conduct. Relying again on *Star Scientific*, the court held that “[b]ecause inequitable conduct renders an entire patent (or even a patent family) unenforceable, as a general rule, this doctrine should only be applied in instances where the patentee’s misconduct resulted in the unfair benefit of receiving an unwarranted claim.”

Continued, next page

***Therasense*: Dismantling the Atomic Bomb of Patent Defenses**

Continued

Therefore, even in cases where the higher standards of materiality and intent are met, the patent still may not be held to be unenforceable if the patent would have issued despite the deliberate failure of the patentee to disclose the reference. The court did, however, set forth an exception to the requirement of finding but-for materiality, holding that in cases of affirmative acts of egregious misconduct, the misconduct will be deemed material. In such cases, inequitable conduct may be found without proving that the undisclosed information meets the but-for materiality test.

After setting forth the higher standard for finding inequitable conduct, the court reversed the district court's findings of inequitable conduct and remanded with instructions to the district court to determine whether the EPO briefs are material under the but-for standard, whether the prosecuting attorney or Abbott's Director of R&D knew of the EPO briefs, and whether the prosecuting attorney or Abbott's Director of R&D made a conscious decision not to disclose the briefs to the PTO in order to deceive the PTO.

Concurring and Dissenting Opinions

1. Concurring In Part, Dissenting In Part

Judge O'Malley wrote a separate concurring-in-part, dissenting-in-part opinion. In the concurring portion of the opinion, she agreed with the majority that (1) intent to deceive and materiality are separate requirements, (2) that the sliding scale test may not be used, (3) that intent to deceive may not be inferred from materiality alone, and (4) that intent may be inferred from circumstantial and indirect evidence only where it is the single most reasonable inference able to be drawn from the evidence.

In the dissenting portion of the opinion written by Judge O'Malley, she disagreed with the majority on the but-for materiality standard and on the remedy for inequitable conduct. She essentially argued that the but-for materiality test and the remedy for inequitable conduct adopted by the majority are too inflexible to comport with principles of equity adopted by the U.S. Supreme Court. With respect to the but-for materiality standard, she argued that *conduct* should be deemed material where:

(1) but for the conduct (whether it be in the form of an affirmative act or intentional non-disclosure), the patent would not have issued (as Chief Judge Rader explains that concept in the majority opinion); (2) the conduct constitutes a false or misleading representation of fact (rendered so either because the statement made is false on its face or information is omitted which, if known, would render the representation false or misleading); or (3) the district court finds that the behavior is so offensive that the court is left with a firm conviction that the integrity of the PTO process as to the application at issue was wholly undermined.

Thus, Judge O'Malley argued for a more flexible standard for materiality than that adopted by the majority.

With respect to the remedy for inequitable conduct, Judge O'Malley also argued for a more flexible approach, stating that a district court should be allowed to choose "to render fewer than all claims unenforceable, may simply dismiss the action before it, or may fashion some other reasonable remedy," so long as the remedy imposed by the court is commensurate with the violation.

2. Dissenting Opinion

Judge Bryson wrote a separate dissenting opinion in which Judges Gajarsa, Dyk and Prost joined. The dissent substantially agreed with the majority's higher standard for intent to deceive, i.e., that a showing of specific intent to deceive the PTO is required, that negligence or even gross negligence is not enough, that both specific intent and materiality must be separately shown by clear and convincing evidence, and that the sliding scale approach should not be used.

With respect to the but-for materiality standard adopted by the majority, the dissent sharply disagreed with the majority on the issue. The dissent argued that the court has always looked to PTO Rule 56 as the standard for defining materiality in cases involving failure to disclose information to the PTO. PTO Rule 56, in its current form, defines information as material if (1) it establishes a prima facie case of unpatentability, or (2) it refutes or is inconsistent with a position taken by the applicant in opposing an argument of unpatentability relied on by the PTO or in asserting an argument of patentability. The dissent argued that the materiality standard set forth in PTO Rule 56 should be the standard applied by the courts because (1) the PTO is in the best position to know what information examiners need to conduct effective and efficient examinations, and (2) the higher materiality standard adopted by the majority will not provide sufficient incentives for applicants to comply with disclosure obligations that are placed on them by the PTO.

The dissent argued that the higher standard adopted by the majority nearly abolishes, rather than reforms, the inequitable conduct doctrine:

[I]f a failure to disclose constitutes inequitable conduct only when a proper disclosure would result in rejection of a claim, there will be little incentive for applicants to be candid with the PTO, because in most instances the sanction of inequitable conduct will apply only if the claims that issue are invalid anyway. For example, under the "but for" test of materiality, an applicant considering whether to disclose facts about a possible prior use of the invention would have little reason to disclose those facts to the PTO. If the applicant remained silent about the prior use, the patent issued, and the prior use was never discovered, the applicant would benefit from the nondisclosure. But even if the prior use was discovered during litigation, the failure to disclose would be held to constitute inequitable

Continued, next page

***Therasense*: Dismantling the Atomic Bomb of Patent Defenses**

Continued

conduct only if the prior use otherwise rendered the relevant claims invalid. The applicant would thus lose nothing by concealing the prior use from the PTO, because he would not be at risk of losing the right to enforce an otherwise valid patent.

As pointed out by the dissent, in many cases the majority's but-for materiality standard will only be met when the claim is invalid anyway in view of the prior art. This, however, is not necessarily the case. As indicated above, under the standard adopted by the majority, a reference is material if the reference taken alone or in combination with other prior art would render a claim invalid by a preponderance of the evidence. A court, however, determines invalidity based on the clear and convincing evidence standard. Therefore, there may very well be situations where the majority's but-for materiality standard is met even though a court would not find the claim to be invalid.

Effect of the En Banc *Therasense* Ruling

Because the district courts and the Federal Circuit are obliged to follow Federal Circuit precedent, the *Therasense* decision should make it much more difficult for defendants to succeed on the inequitable conduct defense and should result in fewer inequitable conduct defenses being asserted. In order to succeed on inequitable conduct defenses, defendants will be required to show by clear and convincing evidence that undisclosed information taken alone or in combination with other references would more likely than not have rendered a claim unpatentable, that the applicant knew of the information, and that the applicant deliberately failed to disclose the reference to the PTO in order to deceive the PTO. If the defendant is relying on circumstantial evidence to show intent, then the defendant will have to show that the single most reasonable inference to be drawn from the evidence is that the patentee intended to deceive the PTO by withholding the prior art.

In addition, even if the defendant can meet this heavy burden, the defendant will not succeed on the defense unless the misconduct resulted in the unfair benefit of receiving an unwarranted claim. Therefore, if the patent would have issued despite the misconduct, the patent will not be held to be unenforceable.

However, if a defendant can show that the patentee engaged in affirmative egregious acts of misconduct, then the defendant will not need to show that the information meets the but-for materiality standard. Therefore, in cases where the defendant can show that the patentee intentionally misled the PTO and that the deception resulted in the patentee receiving an unwarranted claim, the defendant should prevail on the inequitable conduct defense.

The decision should also have the effect of drastically reducing the amount of information that applicants are required to disclose to the PTO. Decisions by the CAFC in recent cases such as *McKesson Information Services, Inc. v Bridge Medical, Inc.* (Fed. Cir. 2007) have created incentives for applicants to over-disclose information to the PTO, even if the information is only of marginal

value, if that. For example, many applicants, especially large corporations with large patent portfolios, err on the side of caution by cross-citing applications that arguably have some related subject matter, but that are not related as parent/child applications or as foreign counterparts. In addition to cross-citing the applications themselves, applicants have been faced with the daunting task of also cross-citing any prior art, office actions, search reports, responses, or other potentially relevant information cited in the cross-cited applications. This has resulted in exponential increases in the amounts and types of information that applicants cite to the PTO, even if the information is not known to be relevant to patentability. The decision in *Therasense* should greatly reduce this burden.



In addition, a few days after the *Therasense* decision was handed down, the PTO announced that it would be studying the decision and would soon issue guidance to applicants as to the prior art and information they must disclose to the PTO to meet information disclosure requirements. It seems likely that the PTO will revise PTO Rule 56 to comport with the decision, possibly by revising the definition of materiality in Rule 56 to be consistent with the but-for materiality standard adopted by the majority. If that happens, much of the disagreement between the dissent and the majority in *Therasense* would become moot.

Because the decision was split, however, many practitioners may be left wondering whether future CAFC panels will deviate from the majority decision in *Therasense*. I suppose only time will tell. It should be of some comfort to practitioners and to patentees that the dissent agreed with the majority on the higher standard for intent. Therefore, even if district courts and even the CAFC deviate in the manner in which they apply the materiality standard, there should at least be uniformity in applying the higher intent standard. Consequently, the decision should curb the overuse of the inequitable conduct defense and reduce the disclosure burdens experienced by practitioners and patentees.

Dan Santos is a partner at the intellectual property boutique of Smith Risley Tempel Santos LLC. His practice includes preparation and prosecution of patent applications, performing infringement and validity analyses, drafting of opinions, and litigation support. He counsels clients and renders opinions concerning the infringement/non-infringement of issued patents, the validity/invalidity of issued patents, and the design of products and processes to avoid potential patent infringement assertions. His practice focuses primarily on patents in electrical, software and optical technologies. Dan can be contacted by email at dsantos@srtslaw.com or by phone at (770)709-0013.

This article previously appeared in the July 2011 issue of Intellectual Property Today.

In Memoriam...

When Philip Walden, Jr. tragically passed away on June 7, 2011, we lost a valuable and influential member of the Georgia Intellectual Property Bar. Over the past 20 years, Philip has been in private practice (King & Spalding and Jones & Walden), running a major record label (Capricorn Records), and most recently in house (Turner Broadcasting's Music Group). Philip was a regular speaker and attendee at IP Bar events, including the annual IP Bar Seminar in November.



Philip Michael Walden, Jr.
1962 - 2011

I had the privilege and honor of being his co-worker, his outside counsel, his business partner and his friend. Philip and I were summer associates together and then started as first year associates on the Intellectual Property Team at King & Spalding in 1992. Philip was smart and hard working, but he always remained devoted to his family. He is survived by his wife Melissa, and his four children -- Lily (21), Rachel (17), Philip Michael (14) and Jarrett (8).

Before law school, Philip had grown up around his dad's record company, Capricorn Records. Despite his larger than life roots, he remained straight-forward,

humble and even disarming. He always seemed to have a great positive energy.

Philip left King & Spalding when his dad needed him to run Capricorn Records in the mid-1990s. What Philip did there was nothing short of remarkable. He reinvigorated the label and introduced the world to some great music like Widespread Panic, Cake, 311 and The Freddy Jones Band. While the bands were the stars on stage, Philip was the star behind the scenes. He turned Capricorn around and eventually sold the label to Zomba/Volcano Records.

Philip returned to private practice with Leon Jones, forming Jones & Walden. But eventually Philip's musical roots called again and he took a job at Turner to handle music issues.

Much has been said and written about Philip's life and its untimely ending in the past few weeks. Perhaps one mutual friend put it best when he said his day was always a little bit brighter when he interacted with Philip. It was true. He will be missed.

- John Herman
Robbins Geller Rudman & Dowd LLP

Thank You!

The Executive Committee of the IP Section would like to acknowledge and express its gratitude to each committee member that served to help make the 2010-2011 year successful.

Licensing Committee:

- Charles Middleton
- Christopher Chan
- Michael Tanenbaum

Website Committee:

- Chris Lightner
- Chris Glass
- Gaylon Hollis
- Michael Tanenbaum

Litigation Committee:

- Tiffany Williams
- Jennifer Liotta
- Ann Fort
- Kristin Goran
- Alyson Wooten
- Steve Hardy
- Nicole Morris
- David Lilienfeld

Copyright Committee:

- Tuneen Chisolm
- Deborah Gonzalez
- Chris Huffines

Patent Committee:

- Nigamnarayan (Nigam) Acharya
- Benjie Balsler
- Andrew Claerbout
- Cory Davis
- Joe Gleason
- John Graves
- Bill Isaacs
- Ryan Pumpian
- Charles Middleton
- Tiffany Williams
- Paul McGowan
- Gibson Lanier
- Wendy Choi
- Ian Wasser
- Thomas McGurk
- Kim Thomason
- Renee Bailey
- Josh Aronson
- Alton Hornsby III
- Michael Tanenbaum
- Kankindi Rwego
- Joseph Long
- Brian Decker
- Arvind Reddy

Section Officers and Committee Chairs 2011-2012

Chairman

A. Shane Nichols
King & Spalding LLP
1180 Peachtree Street, NE
Atlanta, GA 30309
404-572-3507
SNichols@kslaw.com

Chair-Elect

Phillip Burrus
Burrus Intellectual Property Group
460 Grant Street SE
Atlanta, GA 30312
404-797-8111
PBurrus@BurrusIPLaw.com

Vice Chair

Tina McKeon
McKeon, Meunier, Carlin & Curfman, LLC
817 West Peachtree Street NW
Suite 900
Atlanta, GA 30308
404-645-7701
TMcKeon@m2iplaw.com

Secretary

Brad Groff
Gardner Groff Greenwald & Villanueva, P.C.
2018 Powers Ferry Road
Suite 800
Atlanta, GA 30339
404-984-2300
BGroff@gardnergroff.com

Treasurer

Wilson White
Kilpatrick Townsend
1100 Peachtree Street
Suite 2800
Atlanta, GA, 30309
404-815-6607
WWhite@kilpatricktownsend.com

Patent Litigation

George D. Medlock, Jr.
Alston & Bird LLP
One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3424
404-881-7765
George.Medlock@alston.com

Patent Prosecution & Transactional

Rivka Monheit
Pabst Patent Group LLP
1545 Peachtree Street NE
Suite 320
Atlanta, GA 30309
404-879-2150
Rivka@pabstpatent.com

Patent Agents

Susanne Hollinger
Emory University Office of Tech. Transfer
1599 Clifton Road
Atlanta, GA 30322
404-712-1179
SHollin@emory.edu

Trademark

Dinisa Folmar
The Coca-Cola Company
1 Coca Cola Plaza NW
Atlanta, GA 30313
404-676-2351
DFolmar@na.ko.com

Copyright

Joe Staley
Kids II, Inc.
555 North Point Center East, Suite 600
Alpharetta, GA 30022
Joe.Staley@kidsii.com

Bar Relations

Brent Bellows
Knowles Intellectual Property Strategies
400 Perimeter Center Terrace NE, Suite 125
Atlanta, GA 30346
678-694-1558
BBellows@kipsllc.com

Public Relations

Chris Curfman
McKeon, Meunier, Carlin & Curfman, LLC
817 West Peachtree Street NW, Suite 900
Atlanta, GA 30308
404-645-7717
CCurfman@m2iplaw.com

Website

Lauren Fernandez-Staley
CIBA Vision
2930 Amwiler Court
Atlanta, GA 30360-2821
770-984-2300
LaurenFernandez@gmail.com

In-House Counsel

Matt Smith
Converge, Inc.
5390 Triangle Parkway, Suite 300
Norcross, GA 30092
MSmith@converge.com

Academic & Judicial Relations

Tim Holbrook
Emory University School of Law
Gambrell Hall
1301 Clifton Road
Atlanta, GA 30322
404-712-0353
THolbrook@emory.edu

Social

Lauren Estrin
Turner Broadcasting System Inc.
1050 Techwood Drive
Atlanta, GA 30308
Lauren.Estrin@turner.com

Young IP Lawyers

C. Suzanne Werner
King & Spalding LLP
1180 Peachtree Street, NE
Atlanta, GA 30309
404-572-2759
SWerner@kslaw.com